11 – 18 of 18
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2015
-
Mark
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
(
- Contribution to journal › Article
- 2013
-
Mark
Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.
(
- Contribution to journal › Article
- 2011
-
Mark
Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma 63 patients with a minimum follow-up of 4 years
(
- Contribution to journal › Article
- 2010
-
Mark
Genomic Changes in Chromosomes 10, 16, and X in Malignant Peripheral Nerve Sheath Tumors Identify a High-Risk Patient Group.
(
- Contribution to journal › Article
- 2009
-
Mark
Treatment of localized Ewing sarcoma family of tumors The Scandinavian Sarcoma Group experience
(
- Contribution to journal › Article
-
Mark
Scandinavian experience in classical osteosarcoma Results of the SSG XIV protocol
(
- Contribution to journal › Article
-
Mark
Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors
(
- Contribution to journal › Article
- 2006
-
Mark
May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol
(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »